UROV News and Press, Urovant Sciences Ltd. From 03/07/19

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced Chief Executive Officer Keith A. Katkin is scheduled to present a corporate overview at the Cowen and Company 39 th Annual Healthcare ...

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced James Robinson, President and Chief Operating Officer of Alkermes, will join its Board of Directors. This ...

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules ...

Urovant Sciences (UROV) Q3 2018 Earnings Conference Call February 13, 2019, 04:30 PM ET Company Participants Christine Ocampo - Chief Accounting Officer Keith Katkin - CEO Cornelia Haag-Molkenteller - Chief Medical Officer Michael McFadden - Chief Commercial Officer Conferen...

Urovant Sciences (NASDAQ: UROV ): Q3 GAAP EPS of -$0.87 beats by $0.05. More news on: Urovant Sciences, Earnings news and commentary, Healthcare stocks news, Read more ...

Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the three months ended December 31, 2018. Recent Business Highlights Ann...

Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2018 third fiscal quarter financial results after the close of U.S. financial markets on W...